ARCHIVES

EPO Controversy: ODAC To Review EPO Agents in May; SEC Probes Amgen’s Delay in Study Disclosure.

This article is from The Cancer Letter archive.

Vol. 33 No. 08 | March 2, 2007

Download PDF Visit The Full Archive

Related Articles

Amgen Cancels Rilotumumab Trials in Gastric Cancer

December 26, 2014

FDA Panel urges Breast Implant Studies, Says Devices Should Remain Available

November 22, 1991

Letter to the Editor

March 21, 2003

CPRU Program Gets Basic Concept Approval

October 2, 1987

Mammography: Panel Member Quits Over “One-Sided” Document

February 14, 1997

Klausner: “The More We Know About The Causes, The Better We Are at Prevention”

June 27, 1997